1. Home
  2. ONEG vs INTS Comparison

ONEG vs INTS Comparison

Compare ONEG & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OneConstruction Group Limited Ordinary Shares

ONEG

OneConstruction Group Limited Ordinary Shares

SELL

Current Price

$1.09

Market Cap

16.5M

ML Signal

SELL

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

SELL

Current Price

$2.46

Market Cap

13.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ONEG
INTS
Founded
2021
2012
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.5M
13.7M
IPO Year
2024
2021

Fundamental Metrics

Financial Performance
Metric
ONEG
INTS
Price
$1.09
$2.46
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $18.67
AVG Volume (30 Days)
★ 5.2M
13.8K
Earning Date
07-23-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.64
$0.22
52 Week High
$14.95
$8.06

Technical Indicators

Market Signals
Indicator
ONEG
INTS
Relative Strength Index (RSI) 49.17 28.84
Support Level $0.94 $0.22
Resistance Level $1.97 $4.17
Average True Range (ATR) 0.14 0.27
MACD -0.02 -0.06
Stochastic Oscillator 8.11 13.88

Price Performance

Historical Comparison
ONEG
INTS

About ONEG OneConstruction Group Limited Ordinary Shares

OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. The company is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction projects include performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Share on Social Networks: